Rare cancers and GBM, the most common and aggressive brain cancer, both have a highly negative health and economic impact and the lowest 5-year survival rate among all cancers. Theriac is going to be a cost-effective theranostic approach, with a high safety profile, high sensitivity and specificity and simultaneous monitoring of the disease progression, too.

Further Activities to have a look at